Statin use and risk of pancreatic cancer: a meta-analysis
Statin use and risk of pancreatic cancer: a meta-analysis
复制标题
DOI：
10.1007/s10552-012-9979-9
复制
发表时间：
2012-07-01
影响因子：
2.3
通讯作者：
Jiang, Bo
中科院分区：
文献类型：
--
作者：
Cui, Xiaobing;Xie, Yue;Jiang, Bo
他汀类药物是常用的处方药物，可有效降低胆固醇水平和心血管事件的风险。临床前研究表明他汀类药物还具有癌症化学预防特性。然而，关于他汀类药物是否会影响胰腺癌的风险，临床研究提供了相互矛盾的结果。在此，我们提出这项荟萃分析，以评估他汀类药物的使用与胰腺癌风险之间的关联。我们对截至 2011 年 8 月的合格研究进行了全面检索。使用逆方差加权随机效应模型计算汇总相对风险 (RR) 估计值和相应的 95% 置信区间 (CI)。在有数据的情况下进行亚组分析。通过 Cochran's Q 检验和 I (2) 统计来评估异质性。我们纳入了 16 项研究，涉及 1,692,863 名参与者和 7,807 例胰腺癌病例。汇总结果仅表明所有他汀类药物使用者的胰腺癌风险没有显着降低（RR 0.89；95% CI，0.74-1.07）。在长期（超过 4 年）随访（RR 0.94，0.81-1.08）和他汀类药物使用（RR 0.97，0.76-1.23）的亚组分析中获得了类似的结果，并且发现亲脂性他汀类药物的使用与胰腺癌风险之间没有关联（RR 1.03，0.92-1.16）。在本荟萃分析中没有观察到发表偏倚的证据。然而，所有研究之间均检测到显着的异质性（p < 0.00001，I (2) = 81 %）。 总之，我们的结果表明，当每日服用他汀类药物预防心血管事件时，他汀类药物的使用与胰腺癌风险之间没有关联。
Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer.We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran's Q test and the I (2) statistic.We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74-1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81-1.08) and statin use (RR 0.97, 0.76-1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92-1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I (2) = 81 %).In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention.